Second-generation BCR-ABL kinase inhibitors in CML

N Engl J Med. 2010 Oct 21;363(17):1673; author reply 1673-5. doi: 10.1056/NEJMc1007927.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Benzamides
  • Dasatinib
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Pyrimidines / therapeutic use*
  • Remission Induction
  • Thiazoles / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • nilotinib
  • Dasatinib